应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02617 药捷安康-B
休市中 11-20 16:08:29
6.450
-0.290
-4.30%
最高
6.700
最低
6.345
成交量
252.00万
今开
6.390
昨收
6.740
日振幅
5.27%
总市值
26.32亿
流通市值
20.19亿
总股本
4.08亿
成交额
1,627万
换手率
0.81%
流通股本
3.13亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
药捷安康-B(02617.HK)存仓市值总计1.63亿港元 股东将2345万股股票存入中国证券登记结算香港
智通财经 · 11-20 08:15
药捷安康-B(02617.HK)存仓市值总计1.63亿港元 股东将2345万股股票存入中国证券登记结算香港
药捷安康-B(02617)存仓市值总计1.63亿港元 股东将2345万股股票存入中国证券登记结算香港
智通财经 · 11-20 08:15
药捷安康-B(02617)存仓市值总计1.63亿港元 股东将2345万股股票存入中国证券登记结算香港
药捷安康-B将44,971,128股非上市股份转换为H股,已发行股本增至357,401,301股
公告速递 · 11-19 20:32
药捷安康-B将44,971,128股非上市股份转换为H股,已发行股本增至357,401,301股
药捷安康-B(02617.HK)转换4497.11万股非上市股份为H股
智通财经 · 11-19 20:31
药捷安康-B(02617.HK)转换4497.11万股非上市股份为H股
药捷安康-B(02617):完成H股全流通
智通财经 · 11-19 18:18
药捷安康-B(02617):完成H股全流通
药捷安康-B盘中涨超5%,前三季度制药板块归母净利润同比增长52%
同花顺 · 11-05
药捷安康-B盘中涨超5%,前三季度制药板块归母净利润同比增长52%
药捷安康-B披露2026年10月股份变动月报表,总股本增至408,578,633股
公告速递 · 11-03
药捷安康-B披露2026年10月股份变动月报表,总股本增至408,578,633股
药捷安康-B:11月2日回购5.65万股,耗资约45.46万港元
公告速递 · 11-02
药捷安康-B:11月2日回购5.65万股,耗资约45.46万港元
药捷安康-B(02617)11月2日斥资45.46万港元回购5.65万股
智通财经 · 11-02
药捷安康-B(02617)11月2日斥资45.46万港元回购5.65万股
药捷安康-B(02617.HK):联交所授出实行H股全流通的上市批准
中金财经 · 11-01
药捷安康-B(02617.HK):联交所授出实行H股全流通的上市批准
药捷安康-B(02617.HK):联交所授出实行H股全流通的上市批准
智通财经 · 11-01
药捷安康-B(02617.HK):联交所授出实行H股全流通的上市批准
药捷安康:4497万股非上市股份转H股获批 H股占比将升至87.70%
财中社 · 11-01
药捷安康:4497万股非上市股份转H股获批 H股占比将升至87.70%
药捷安康-B回购3.25万股股份,总额约28.03万港元
公告速递 · 10-27
药捷安康-B回购3.25万股股份,总额约28.03万港元
药捷安康-B:收到中国证监会H股全流通备案通知书 涉及4497.11万股
南方财经网 · 10-26
药捷安康-B:收到中国证监会H股全流通备案通知书 涉及4497.11万股
药捷安康-B(02617.HK)收到中国证监会就实施本公司H股全流通发出的备案通知书
智通财经 · 10-26
药捷安康-B(02617.HK)收到中国证监会就实施本公司H股全流通发出的备案通知书
药捷安康-B回购52,500股股份,涉资约46.69万港元
公告速递 · 10-26
药捷安康-B回购52,500股股份,涉资约46.69万港元
药捷安康-B(02617)10月26日斥资46.7万港元回购5.25万股
智通财经 · 10-26
药捷安康-B(02617)10月26日斥资46.7万港元回购5.25万股
药捷安康-B(02617.HK)10月26日斥资46.7万港元回购5.25万股
智通财经 · 10-26
药捷安康-B(02617.HK)10月26日斥资46.7万港元回购5.25万股
药捷安康-B回购52,500股股份,涉资约45.87万港元
公告速递 · 10-23
药捷安康-B回购52,500股股份,涉资约45.87万港元
港股异动 | 药捷安康-B(02617.HK)涨超4% 捷恩泰®已于多个省份开出首批临床处方
智通财经 · 10-23
港股异动 | 药捷安康-B(02617.HK)涨超4% 捷恩泰®已于多个省份开出首批临床处方
暂无数据
公司概况
公司名称:
药捷安康-B
所属市场:
SEHK
上市日期:
--
主营业务:
药捷安康(南京)科技股份有限公司是一家从事生物制药的中国公司,主要专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。该公司的核心产品Tinengotinib是一种处于注册临床阶段的内部发现和开发的MTK抑制剂,适用于某些复发或难治的耐药实体瘤。该公司的肿瘤产品线包括TT-00973(针对 AXL)、TT-01488(用于血液系统恶性肿瘤)、TT-01688(用于炎症性疾病)和 TT-00920(用于慢性心力衰竭)。这些产品能够对多种癌症类型(包括前列腺癌、肝癌、乳腺癌和BTC)产生疗效。它还可用于治疗肝细胞癌、乳腺癌、胆道癌和Pan-FGFR实体瘤。
发行价格:
--
{"stockData":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"药捷安康-B","latestPrice":6.45,"timestamp":1795162109007,"preClose":6.74,"halted":0,"volume":2520000,"delay":0,"changeRate":-0.04302670623145401,"floatShares":313000000,"shares":408000000,"eps":-0.76,"marketStatus":"休市中","change":-0.29,"latestTime":"11-20 16:08:29","open":6.39,"high":6.7,"low":6.345,"amount":16266945,"amplitude":0.052671,"askPrice":6.46,"askSize":6500,"bidPrice":6.45,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":-0.776468,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1795397400000},"marketStatusCode":7,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":6.74,"openAndCloseTimeList":[[1795138200000,1795147200000],[1795150800000,1795161600000]],"volumeRatio":1.1078861269452271,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02617/tweets","defaultTab":"tweets","newsList":[{"id":"2684856186","title":"药捷安康-B(02617.HK)存仓市值总计1.63亿港元 股东将2345万股股票存入中国证券登记结算香港","url":"https://stock-news.laohu8.com/highlight/detail?id=2684856186","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684856186?lang=zh_cn&edition=full","pubTime":"2026-11-20 08:15","pubTimestamp":1795133719,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684186854","title":"药捷安康-B(02617)存仓市值总计1.63亿港元 股东将2345万股股票存入中国证券登记结算香港","url":"https://stock-news.laohu8.com/highlight/detail?id=2684186854","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684186854?lang=zh_cn&edition=full","pubTime":"2026-11-20 08:15","pubTimestamp":1795133719,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,香港联交所最新资料显示,11月19日,药捷安康-B(02617)出现仓位异动,存仓市值总计1.63亿港元,占比7.48%。该公司股东将2345万股股票存入中国证券登记结算香港。药捷安康-B发布公告,于2026年11月19日将4497.11万股非上市股份转换为4497.11万股H股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1526022.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","161027","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137314405","title":"药捷安康-B将44,971,128股非上市股份转换为H股,已发行股本增至357,401,301股","url":"https://stock-news.laohu8.com/highlight/detail?id=1137314405","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1137314405?lang=zh_cn&edition=full","pubTime":"2026-11-19 20:32","pubTimestamp":1795091551,"startTime":"0","endTime":"0","summary":"2026年11月19日,药捷安康-B(02617)发布公告称,公司将44,971,128股非上市股份转换为同等数量的H股,占变动前已发行股份总数的14.39%。本次转换完成后,公司已发行股份由312,430,173股增加至357,401,301股,库藏股保持917,500股,合计达到358,318,801股。\n公司同时披露,经本次转换,原有非上市股份从95,230,960股调整至50,259,832股,减少44,971,128股,减幅为47.22%。公司表示,该事项已获董事会正式授权审批,并符合相关上市规则及法律法规。公告由董事长兼首席执行官吴永谦签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药捷安康-B将44,971,128股非上市股份转换为H股,已发行股本增至357,401,301股","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684082976","title":"药捷安康-B(02617.HK)转换4497.11万股非上市股份为H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2684082976","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684082976?lang=zh_cn&edition=full","pubTime":"2026-11-19 20:31","pubTimestamp":1795091491,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2684274039","title":"药捷安康-B(02617):完成H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2684274039","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2684274039?lang=zh_cn&edition=full","pubTime":"2026-11-19 18:18","pubTimestamp":1795083524,"startTime":"0","endTime":"0","summary":"智通财经APP讯,药捷安康-B(02617)发布公告,将10名参与股东所持有的4497.11万股非上市股份转换为H股已于2026年11月19日完成,而经转换H股于联交所的上市将于2026年11月20日上午九时正开始。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1525744.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681045034","title":"药捷安康-B盘中涨超5%,前三季度制药板块归母净利润同比增长52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2681045034","media":"同花顺","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681045034?lang=zh_cn&edition=full","pubTime":"2026-11-05 15:26","pubTimestamp":1793863560,"startTime":"0","endTime":"0","summary":"11月5日,药捷安康-B(02617.HK)盘中涨超5%,截至15时21分,涨5.23%,报8.345港元/股,成交额4615.25万港元。医药板块三季报业绩拐点与创新药临床数据集中释放形成共振,2026年前三季度制药 ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun_highlight","url":"http://news.10jqka.com.cn/20261105/c681500850.shtml","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://news.10jqka.com.cn/20261105/c681500850.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun_highlight","symbols":["02617","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101315826","title":"药捷安康-B披露2026年10月股份变动月报表,总股本增至408,578,633股","url":"https://stock-news.laohu8.com/highlight/detail?id=1101315826","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1101315826?lang=zh_cn&edition=full","pubTime":"2026-11-03 19:46","pubTimestamp":1793706364,"startTime":"0","endTime":"0","summary":"药捷安康(南京)科技股份有限公司于2026年11月3日发布2026年10月股份变动月报表,报告期截至2026年10月31日。公司在报告期内,H股的法定/注册股份数量由期初的312,687,673股增至期末的313,347,673股,增加660,000股;非上市股份的总数则维持95,230,960股不变。截至10月底,公司法定/注册股本规模增至408,578,633股。该变动主要来自2026年H股奖励计划股份奖励下新增发行660,000股,同时公司在本月内通过多次回购累计回购143,000股并将其作为库存股份持有,未予注销。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144653195","title":"药捷安康-B:11月2日回购5.65万股,耗资约45.46万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1144653195","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144653195?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:10","pubTimestamp":1793617858,"startTime":"0","endTime":"0","summary":"药捷安康(南京)科技股份有限公司于2026年11月2日公告进行了股份购回。公司当日于香港联交所场内回购5.65万股,占已发行股本约0.02%。回购价格在每股港币7.95元至8.20元之间,总金额约为45.46万港元。根据2026年6月18日通过的购回授权,药捷安康-B可回购的股份总数为31,268,767股,截至目前已累计回购917,500股,约占授权通过当日公司已发行股本总数的0.29%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药捷安康-B:11月2日回购5.65万股,耗资约45.46万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680675505","title":"药捷安康-B(02617)11月2日斥资45.46万港元回购5.65万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2680675505","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680675505?lang=zh_cn&edition=full","pubTime":"2026-11-02 19:08","pubTimestamp":1793617706,"startTime":"0","endTime":"0","summary":"智通财经APP讯,药捷安康-B(02617)发布公告,于2026年11月2日斥资45.46万港元回购5.65万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1517318.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680720168","title":"药捷安康-B(02617.HK):联交所授出实行H股全流通的上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2680720168","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680720168?lang=zh_cn&edition=full","pubTime":"2026-11-01 19:58","pubTimestamp":1793534283,"startTime":"0","endTime":"0","summary":"格隆汇11月1日丨药捷安康-B(02617.HK)公告,董事会欣然宣布,联交所已授出由公司10名股东(\"参与股东\")所持有的44,971,128股非上市股份转换而成的44,971,128股H股上市及买卖批准。联交所于2026年10月30日授出上市批准。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20261101/32412899.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02617","IPOS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680209677","title":"药捷安康-B(02617.HK):联交所授出实行H股全流通的上市批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2680209677","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680209677?lang=zh_cn&edition=full","pubTime":"2026-11-01 18:40","pubTimestamp":1793529641,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680209716","title":"药捷安康:4497万股非上市股份转H股获批 H股占比将升至87.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2680209716","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680209716?lang=zh_cn&edition=full","pubTime":"2026-11-01 18:35","pubTimestamp":1793529300,"startTime":"0","endTime":"0","summary":"11月1日,药捷安康-B(02617)发布公告,联交所已授出本公司10名股东所持有的4497万股非上市股份转为H股的上市批准,上述股份占本公司已发行股本总额约11.01%。转换后本公司H股的股份数目将由3.13亿股增至3.58亿股,占比将由76.69%上升至87.70%。非上市股份将减少至5026万股,占比下降至12.30%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202611013917734910.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202611013917734910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113668038","title":"药捷安康-B回购3.25万股股份,总额约28.03万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1113668038","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113668038?lang=zh_cn&edition=full","pubTime":"2026-10-27 19:01","pubTimestamp":1793098896,"startTime":"0","endTime":"0","summary":"药捷安康-B于2026年10月27日发布公告,披露公司当日通过香港联交所场内回购3.25万股H股,约占回购前已发行股本的0.01%。每股回购价区间为8.53港元至8.72港元,本次回购合计支付280,290.01港元,折合约28.03万港元。药捷安康-B于2026年6月18日获股东大会授权可回购31,268,767股,当前已回购的股份数累计达861,000股,占授权规模的0.28%。公司确认已严格遵守香港联交所证券上市规则及相关法律法规,相关回购事宜均经公司董事会批准。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药捷安康-B回购3.25万股股份,总额约28.03万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678194239","title":"药捷安康-B:收到中国证监会H股全流通备案通知书 涉及4497.11万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678194239","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678194239?lang=zh_cn&edition=full","pubTime":"2026-10-26 22:51","pubTimestamp":1793026260,"startTime":"0","endTime":"0","summary":"南财智讯10月26日电,药捷安康-B(02617.HK)发布内幕消息公告,公司建议将10名股东持有的4497.11万股内资股(占公司已发行股本总额约11.01%)实施H股全流通。公司于2026年10月26日收到中国证监会就实施H股全流通发出的备案通知书,已完成上述4497.11万股内资股转换为H股的实施备案。备案通知书有效期为自发出日期起计12个月。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202610263908633664.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202610263908633664.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678194155","title":"药捷安康-B(02617.HK)收到中国证监会就实施本公司H股全流通发出的备案通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2678194155","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678194155?lang=zh_cn&edition=full","pubTime":"2026-10-26 22:50","pubTimestamp":1793026200,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147010453","title":"药捷安康-B回购52,500股股份,涉资约46.69万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1147010453","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147010453?lang=zh_cn&edition=full","pubTime":"2026-10-26 20:12","pubTimestamp":1793016724,"startTime":"0","endTime":"0","summary":"药捷安康(南京)科技股份有限公司于2026年10月26日向香港联合交易所提交翌日报表,披露当日于场内执行股份回购,导致已发行股本出现变动。公司于2026年10月26日回购H股普通股52,500股,约占回购前公司已发行股份总数的0.02%。每股价格在8.77港元至8.965港元之间,总耗资约46.69万港元。本次回购完成后,公司已发行股份总数变更为312,519,173股,库藏股数量则增至828,500股,合计股份数量为313,347,673股。回购授权于2026年6月18日获得股东大会通过,授权回购股份总数为31,268,767股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药捷安康-B回购52,500股股份,涉资约46.69万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678980671","title":"药捷安康-B(02617)10月26日斥资46.7万港元回购5.25万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678980671","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678980671?lang=zh_cn&edition=full","pubTime":"2026-10-26 20:11","pubTimestamp":1793016668,"startTime":"0","endTime":"0","summary":"智通财经APP讯,药捷安康-B(02617)发布公告,于2026年10月26日斥资46.7万港元回购5.25万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1512684.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678119806","title":"药捷安康-B(02617.HK)10月26日斥资46.7万港元回购5.25万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2678119806","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678119806?lang=zh_cn&edition=full","pubTime":"2026-10-26 20:11","pubTimestamp":1793016668,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1197503780","title":"药捷安康-B回购52,500股股份,涉资约45.87万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1197503780","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197503780?lang=zh_cn&edition=full","pubTime":"2026-10-23 17:07","pubTimestamp":1792746437,"startTime":"0","endTime":"0","summary":"药捷安康(南京)科技股份有限公司于2026年10月23日公告披露,公司于当日通过香港联交所场内回购股份52,500股,约占现有已发行股份的0.02%。本次回购价格区间为每股8.55港元至8.79港元,合计耗资约45.87万港元。回购完成后,公司已发行股份总数仍为313,347,673股,其中不包括库存股份的已发行股份数为312,571,673股,库存股份数增至776,000股。公司表示,本次回购已获得董事会正式授权,并遵守了香港联交所相关上市规则及适用的法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药捷安康-B回购52,500股股份,涉资约45.87万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677494364","title":"港股异动 | 药捷安康-B(02617.HK)涨超4% 捷恩泰®已于多个省份开出首批临床处方","url":"https://stock-news.laohu8.com/highlight/detail?id=2677494364","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677494364?lang=zh_cn&edition=full","pubTime":"2026-10-23 14:26","pubTimestamp":1792736810,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":-0.1485},{"period":"1month","weight":-0.2889},{"period":"3month","weight":-0.3744},{"period":"6month","weight":-0.8494},{"period":"1year","weight":-0.97},{"period":"ytd","weight":-0.9439}],"compareEarnings":[{"period":"1week","weight":-0.0519},{"period":"1month","weight":-0.0525},{"period":"3month","weight":-0.1384},{"period":"6month","weight":-0.1248},{"period":"1year","weight":-0.1326},{"period":"ytd","weight":-0.1256}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药捷安康(南京)科技股份有限公司是一家从事生物制药的中国公司,主要专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。该公司的核心产品Tinengotinib是一种处于注册临床阶段的内部发现和开发的MTK抑制剂,适用于某些复发或难治的耐药实体瘤。该公司的肿瘤产品线包括TT-00973(针对 AXL)、TT-01488(用于血液系统恶性肿瘤)、TT-01688(用于炎症性疾病)和 TT-00920(用于慢性心力衰竭)。这些产品能够对多种癌症类型(包括前列腺癌、肝癌、乳腺癌和BTC)产生疗效。它还可用于治疗肝细胞癌、乳腺癌、胆道癌和Pan-FGFR实体瘤。","exchange":"SEHK","name":"药捷安康-B","nameEN":"TRANSTHERA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.54.0","shortVersion":"4.54.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药捷安康-B,02617,药捷安康-B股票,药捷安康-B股票老虎,药捷安康-B股票老虎国际,药捷安康-B行情,药捷安康-B股票行情,药捷安康-B股价,药捷安康-B股市,药捷安康-B股票价格,药捷安康-B股票交易,药捷安康-B股票购买,药捷安康-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}